Dr. Litton on Responses to Talazoparib in BRCA1/2+ Early TNBC

Jennifer Litton, MD

Jennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.

Jennifer Litton, MD, a breast medical oncology professor at The University of Texas MD Anderson Cancer Center, highlights responses to talazoparib (Talzenna) seen in patients with BRCA1/2-positive, early triple-negative breast cancer (TNBC).

Talazoparib was evaluated as part of a phase 2 study (NCT03499353) in patients with TNBC and yielded a pathologic complete response (pCR) rate, by independent central review, of 45.8% in the evaluable patient population, and 49.2% in the intent to treat population, Litton explains. When assessed by study investigators, the pCR was 45.8% in the evaluable population, and 47.5% in the intent to treat population.

This translates to a 45% to 50% pCR rate for patients with TNBC following treatment with a single agent, Litton concludes.